Pure Global
NCT01158300

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Pediatric Brain Tumor Consortium·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Brain and Central Nervous System Tumors
Drug/Device/Intervention
VEGF inhibitor PTC299
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Pediatric Brain Tumor Consortium
Location
San Francisco,Washington,Chicago,Durham,Philadelphia,Pittsburgh,Memphis,Houston, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Nov 01, 2010
End date
Jan 01, 2015
Enrollment
28 participants
Primary outcome

Maximum-tolerated dose,Adverse events

Summary

RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor.
 
 PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in
 treating young patients with recurrent or refractory primary central nervous system tumors.

ICD-10 classifications
Malignant neoplasm: Overlapping lesion of brain and other parts of central nervous systemMalignant neoplasm: Central nervous system, unspecifiedBenign neoplasm of brain and other parts of central nervous systemMalignant neoplasm of brainSecondary malignant neoplasm of other and unspecified parts of nervous system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01158300
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01158300 through Pure Global AI's free database. This Phase 1 trial is sponsored by Pediatric Brain Tumor Consortium and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.